Table 1:
Demographics of post-QC samples used in the joint analysis.
| Cohort | # Samples | Avg. Age | % Male | % APOE4+ | #CO | #AD | #ADAD | #ADRD | #PD | #OT |
|---|---|---|---|---|---|---|---|---|---|---|
| ADNI | 689 | 73.7 (SD 7.5) | 58.2 | 50.2 | 149 | 521 | 0 | 0 | 0 | 19 |
| Barcelona-1 | 198 | 68.9 (SD 7.4) | 52.5 | 40.4 | 4 | 63 | 0 | 56 | 1 | 74 |
| DIAN | 195 | 38.6 (SD 10.9) | 48.4 | 27.2 | 76 | 2 | 116 | 0 | 0 | 1 |
| FACE | 439 | 71.9 (SD 8.3) | 41.0 | 35.8 | 128 | 239 | 0 | 0 | 0 | 72 |
| Knight-ADRC (Oct 2021) | 805 | 71.3 (SD 8.7) | 46.6 | 39.3 | 566 | 175 | 2 | 13 | 3 | 46 |
| Knight-ADRC (June 2023) | 47 | 72.9 (SD 7.6) | 59.6 | 38.3 | 40 | 7 | 0 | 0 | 0 | 0 |
| MARS | 176 | 66.4 (SD 8.9) | 54.0 | 20.5 | 0 | 0 | 0 | 0 | 0 | 176 |
| PPMI | 785 | 61.8 (SD 9.4) | 57.7 | 22.2 | 157 | 0 | 0 | 0 | 627 | 1 |
| Stanford | 172 | 69.5 (SD 6.2) | 40.7 | 40.7 | 123 | 14 | 0 | 2 | 15 | 18 |
|
| ||||||||||
| Total | 3506 | 67.5 (SD 11.8) | 51.4 | 35.7 | 1243 | 1021 | 118 | 71 | 646 | 407 |
ADNI: Alzheimer’s disease Neuroimaging Initiative; PPMI: Parkinson’s Progression Markers Initiative; FACE: Ace Alzheimer Center Barcelona; DIAN: Dominantly-Inherited Alzheimer’s Network; Knight-ADRC: Knight ADRC Memory and Aging Project; MARS: Washington University Movement Disorder Clinic; Stanford: Stanford Iqbal Farrukh and Asad Jamal ADRC and Aging Memory Study
%APOE4+: Percentage of individuals who are carriers of at least one C allele at rs429358.
#CO: Number of cognitively normal individuals
#AD: Number of individuals affected with late-onset Alzheimer’s disease, as determined by clinical status
#ADAD: Number of individuals affected with early-onset Alzheimer’s disease
#ADRD: Number of individuals affected with non-AD dementia (including frontotemporal dementia, lewy body dementia, etc.)
#PD: Number of individuals affected with Parkinson’s disease
#OT: Number of individuals with unclear pathology